Illumina, Inc. (NASDAQ:ILMN) Shares Bought by MetLife Investment Management LLC

MetLife Investment Management LLC increased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 8.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 89,418 shares of the life sciences company's stock after buying an additional 7,083 shares during the period. MetLife Investment Management LLC owned about 0.06% of Illumina worth $11,949,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Bleakley Financial Group LLC purchased a new stake in Illumina in the 4th quarter worth $751,000. Van ECK Associates Corp increased its holdings in shares of Illumina by 17.5% in the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock worth $20,347,000 after purchasing an additional 22,718 shares during the last quarter. Strategic Financial Concepts LLC purchased a new stake in shares of Illumina in the fourth quarter worth about $1,464,000. Allworth Financial LP boosted its stake in Illumina by 720.7% during the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after buying an additional 6,263 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Illumina during the 4th quarter valued at approximately $448,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently commented on ILMN. Morgan Stanley lowered their target price on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 11th. Royal Bank of Canada dropped their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, April 8th. Canaccord Genuity Group lowered their price target on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a report on Tuesday, March 11th. Piper Sandler boosted their price objective on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Finally, Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Illumina presently has an average rating of "Moderate Buy" and a consensus target price of $138.70.

Illumina Stock Down 0.3 %

NASDAQ:ILMN traded down $0.26 during mid-day trading on Friday, reaching $77.35. The company's stock had a trading volume of 1,424,483 shares, compared to its average volume of 2,280,770. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The stock has a fifty day moving average of $82.02 and a 200-day moving average of $118.20. The firm has a market capitalization of $12.24 billion, a PE ratio of -10.07, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.